# A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease

> **NCT07743580** · PHASE3 · RECRUITING · sponsor: **Shionogi** · enrollment: 2000 (estimated)

## Conditions studied

- SARS-CoV-2

## Interventions

- **DRUG:** Secutrelvir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07743580
- **Lead sponsor:** Shionogi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-14
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2026-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07743580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07743580, "A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07743580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*